Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IxaPD in first relapsed multiple myeloma
ChiCTR2100054121Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixazomib, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
ixazomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100054121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054121.